Case (year) | Age /Sex | Immuno- Suppressant regimen | Time to PML onset from transplantation (Mo) | Clinical Symptoms | Method of diagnosis (specimen) | Reduced immunosupressant as therapy | Treatment for PML | From PML onset to diagnosis (Mo) | Outcome (cause of death/ period from onset to death; Mo) |
---|---|---|---|---|---|---|---|---|---|
Ouwens JP (2000) [3] | 43/M | AZA CsA CS | 15 | Visual loss, seizure, visual hallucination, ataxia, rt.paresis, dysarthria, memory impairment | PCR (CSF) | RD Change (AZA→MMF→CsA) | - | 13 | Died (PML / 15) |
Waggoner J (2009) [4] | 38/F | AZA,Tac, CS,Alemtuzumab, | 43 | Gait instability (ataxia) Visual changes, confusion | PCR (CSF) | RD | cidofovir mirtazapine | 1.5 ~ 2 | Died (respiratory failure / 5) |
Mateen FJ (2011) [2] | 39/F | - | 42 | Ataxia | PCR (CSF) | RD | mirtazapine, mefloquine | 3 | Died (ND / 9.1) |
Mateen FJ (2011) [2] | 62/F | - | 27 | Memory impairment, Ataxia, lt. hemiparesis | PCR (CSF) | RD | - | < 1 | Died (ND /15.6) |
Lobo LJ (2013) [5] | 61/M | Rituximab CsA MMF CS | 13 | Headache, Malaise Memory impairment | PCR (CSF) | RD | - | ND | Neurologic symptoms exacerbation, move to hospice |
Moua T (2013) [6] | 61/M | Tac CS | 5 | Rt. Hemiparesis & sensory disturbance, cognitive decline, aphasia | ISH (brain biopsy) | RD | cytarabine | 3 | Died (ARE?/ 7) |
Panchabhai TS (2016) [7] | 60/F | Tac CS | 16 | Lt. arm paresis, Memory impairment, visual deficits, emotional lability, | PCR (BALF & CSF) | Change (Tac→rapamycin), Discontinued | - | 2 | Died (respiratory failure: ARE / 3) |
Present case | 60/F | Tac MMF CS | 61 | Apathy | PCR (CSF) | RD | mefloquine | 2 | Died (respiratory failure / 5) |